We have substantial concerns about the final input parameters in cost-effectiveness analysis by Sanofi that was used to support National Institute for Health and Care Excellence (NICE) recommendation caplacizumab acute acquired thrombotic thrombocytopenic purpura, 1 ExcellenceTechnology appraisal guidance TA667: with plasma exchange immunosuppression treating purpura. https://www.nice.org.uk/gu...